DARA BioSciences Announces Launch of Bionect for Treatment of Skin Irritation and Burns Associated With Radiation Therapy for Cancer
06. Juni 2012 08:45 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., June 6, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA"), an emerging oncology and oncology-support specialty pharmaceutical company, announced...
DARA BioSciences Announces New Organizational Responsibilities in Preparation for the Launch of New Products and to Strengthen Product Development Capabilities
29. Mai 2012 08:45 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., May 29, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA"), an emerging oncology and oncology-support specialty pharmaceutical company, today...
DARA BioSciences Reports Financial Results for the First Quarter 2012 and Provides Key Highlights of the Company's Business Milestones
21. Mai 2012 11:04 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., May 21, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA") today announced the financial results for the period ending March 31, 2012. The Company...
DARA BioSciences Announces New Analysis of Patient Self-Reported Diary Results in a Phase 2a Clinical Trial of KRN5500 in Patients With Cancer and Neuropathic Pain
09. Mai 2012 08:45 ET
|
DARA BioSciences, Inc.
External Data Analysis Confirms Earlier Published Drug Efficacy Signal in Patients With Treatment-Refractory Neuropathic Pain
DARA to Continue Phase 2 Development Program After Formulation...
DARA BioSciences Closes $10.25 Million Public Offering and Regains Compliance With NASDAQ's Stockholders' Equity Requirement
01. Mai 2012 08:45 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., May 1, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA") announced that at a closing completed on April 26, 2012, it received $10,250,000 in gross...
DARA BioSciences to Raise $10.1 Million in Public Offering
09. April 2012 09:05 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., April 9, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA") announced that it entered into definitive securities purchase agreements with certain...
DARA BioSciences Obtains U.S. Rights to Co-Promote Bionect(R), an FDA Approved Topical Hyaluronic Acid, Exclusively in the Radiation and Oncology Markets
26. März 2012 08:45 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., March 26, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that it entered into an exclusive agreement with Innocutis Holdings, LLC ("Innocutis") for U.S....
DARA BioSciences Signs Exclusive Agreement With Uman Pharma for U.S. Commercialization Rights to Gemcitabine
15. Februar 2012 08:30 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Feb. 15, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that it entered into an exclusive U.S. agreement with Uman Pharma Inc. for commercial rights to...
DARA BioSciences Signs Definitive Agreement to Raise $1.7 Million in Registered Direct Offering
18. Januar 2012 08:45 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Jan. 18, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) today announced that it has entered into a definitive agreement with one institutional investor providing for the...
DARA BioSciences Announces Acquisition of U.S. Marketing Rights to Soltamox(TM), an FDA Approved Liquid Formulation of Tamoxifen for the Treatment of Breast Cancer
17. Januar 2012 08:45 ET
|
DARA BioSciences, Inc.
Soltamox™ and Other Product Opportunities Enabled Through Acquisition of Oncogenerix, a Private South Carolina-Based Oncology Company
Additional Opportunities to Develop and Distribute...